Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients Attending Chest Clinics in Osun-State, Nigeria
- PMID: 32101120
- DOI: 10.2174/1389201021666200226100242
Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients Attending Chest Clinics in Osun-State, Nigeria
Abstract
Background: The development of multidrug-resistant tuberculosis (MDR-TB) poses a considerable threat to tuberculosis control programmes in Nigeria. There is an increase in the prevalence of MDR-TB worldwide both among new tuberculosis cases as well as previously-treated ones. There is also a rise in transmission of resistant strains due to an increase in MDR-TB patients largely due to the poor drug compliance and the impact of Human immunodeficiency virus infection. Therefore, we intend to determine the extent of MDR-TB among attendees of chest clinics in Osun-State, Nigeria.
Objectives: The objective of this study was to determine the prevalence of MDR-TB among confirmed tuberculosis patients attending chest clinics in Osun-State, Nigeria.
Methods: This study was conducted among 207 attendees of chest clinics in Osun-State between June, 2015 and October 15, 2016. Sputum and blood samples of the participants were collected. GeneXpert test was carried out first on the samples for simultaneous identification of MTB and rifampicin resistance. Sputum samples were cultured on Lowenstein-Jensen (L-J) medium using N-acetyl-Lcysteine- sodium hydroxide (NALC-NaOH) decontamination method. Drug susceptibility testing (DST) to three first-line drugs was carried out using the proportion DST method.
Results: The prevalence of MTB was found to be 27.5% while the prevalence of MDR-TB from the fifty-seven isolates was 10.5%. Previously treated and new cases had a prevalence of 7.0% and 3.5% MDR-TB, respectively. Seventy (33.8%) participants were positive for HIV infection, out of which twenty-six (12.6%) had co-infection of tuberculosis and HIV. The mono-resistance rates of the three first-line drugs used were: 5.3% and 8.7% for ethambutol (EMB) and isoniazid (INH), respectively. No isolate had mono-resistance (0%) to rifampicin (RIF).
Conclusion: This study observed the prevalence of 27.5% MTB and a prevalence of 10.5% MDR-TB among the MTB isolates. The prevalence of TB is high in Osun State. MDR-TB prevalence is higher compared with the national estimate of MDR-TB (5.1%) of 2017. Resistant TB is a threat to national tuberculosis control and it is recommended that all the facilities be equipped to cater to its diagnosis.
Keywords: Antituberculous drugs; Bacteria; Chest Clinics; GeneXpert; Mycobacterium; Pulmonology.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Multidrug-resistant tuberculosis in Imo State, Southeast, Nigeria.Niger J Clin Pract. 2020 Aug;23(8):1172-1177. doi: 10.4103/njcp.njcp_192_19. Niger J Clin Pract. 2020. PMID: 32788498
-
Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.PLoS One. 2018 Jun 4;13(6):e0197737. doi: 10.1371/journal.pone.0197737. eCollection 2018. PLoS One. 2018. PMID: 29864118 Free PMC article.
-
Prevalence of rifampicin and isoniazid mono-resistance among cases of pulmonary tuberculosis from Western Uttar Pradesh, North India.Mol Biol Rep. 2024 Oct 24;51(1):1091. doi: 10.1007/s11033-024-10014-9. Mol Biol Rep. 2024. PMID: 39446249
-
Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.Indian J Tuberc. 2020 Dec;67(4S):S16-S22. doi: 10.1016/j.ijtb.2020.11.010. Epub 2020 Nov 28. Indian J Tuberc. 2020. PMID: 33308663 Review.
-
Prevalence and patterns of drug-resistant Mycobacterium tuberculosis in newly diagnosed patients in China: A systematic review and meta-analysis.J Glob Antimicrob Resist. 2024 Sep;38:292-301. doi: 10.1016/j.jgar.2024.05.018. Epub 2024 May 31. J Glob Antimicrob Resist. 2024. PMID: 38825149
Cited by
-
Trend of pulmonary tuberculosis and rifampicin-resistance among tuberculosis presumptive patients in Central Tigray, Ethiopia; 2018 -2023: a six-year retrospective study.Trop Dis Travel Med Vaccines. 2024 Jul 1;10(1):15. doi: 10.1186/s40794-024-00224-1. Trop Dis Travel Med Vaccines. 2024. PMID: 38946006 Free PMC article.
-
Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis.Infect Dis Poverty. 2023 May 25;12(1):57. doi: 10.1186/s40249-023-01107-x. Infect Dis Poverty. 2023. PMID: 37231463 Free PMC article.
-
Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control.Front Public Health. 2024 May 16;12:1374703. doi: 10.3389/fpubh.2024.1374703. eCollection 2024. Front Public Health. 2024. PMID: 38827613 Free PMC article. Review.
-
Non-communicable diseases and resistant tuberculosis, a growing burden among people living with HIV in Eastern Kenya.PLOS Glob Public Health. 2025 Jun 20;5(6):e0004212. doi: 10.1371/journal.pgph.0004212. eCollection 2025. PLOS Glob Public Health. 2025. PMID: 40540501 Free PMC article.
-
Analysis of drug resistance in pulmonary tuberculosis patients with positive sputum tuberculosis culture in Northeast China.Front Pharmacol. 2023 Sep 25;14:1263726. doi: 10.3389/fphar.2023.1263726. eCollection 2023. Front Pharmacol. 2023. PMID: 37818197 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical